The global influenza market totaled $5.6 million in 2017 and is estimated to reach $6.4 million by 2022, growing at a compound annual growth rate (CAGR) of 3.0% for the period of 2017-2022.
-25 data tables and 77 additional tables
-An overview of the global influenza market
-Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
-Identification of segments with high growth potential and their future applications
-Explanation of major drivers and regional dynamics of the market and current trends within the industry
-Detailed profiles of major vendors in the market, including Alere Inc., MedImmune, LLC, Cepheid Inc., GlaxoSmithKline plc and Qiagen N.V.
This BCC Research report is designed to be a helpful business tool that provides a thorough evaluation of the market for influenza vaccines, therapeutics and diagnostics. The geographic scope of this study is global, with emphasis on U.S. and European data. The report identifies markets in general segments: Vaccines, Therapeutics and Diagnostics. Each market segment discussion provides detailed information based on product categories, uses of products, forecasts and competitive analyses. Additionally, the study covers some of the most significant issues, trends and market factors.
MELISSA ELDER is a healthcare market analyst specializing in treatments, medical equipment and devices. As a research analyst for more than 20 years, she also worked in medical training and advanced medical technologies. She holds a B.S. degree in business management and is pursuing an MBA in health care management from California Coast University.